Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 17/20 | 0.63 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16569368 | 0.78 | RORC (0.61) | RORCPPARG | |
| SCHEMBL16582383 | 0.77 | RORC (1.00) | RORCPPARGCYP2C9 | |
| SCHEMBL18086810 | 0.75 | ELANE (0.42) | RORCKMT2AALDH1A1GAA | |
| SCHEMBL16569384 | 0.75 | RORC (0.52) | RORCPPARGDOT1LMEN1KMT2A | |
| SCHEMBL16569293 | 0.74 | RORC (0.77) | RORCPPARGDOT1LALDH1A1 | |
| SCHEMBL18399875 | 0.71 | RORC (0.53) | RORCPPARG | |
| SCHEMBL16569322 | 0.69 | RORC (0.67) | RORCPPARG | |
| SCHEMBL16569164 | 0.67 | ALDH1A1 (0.53) | RORCPPARGMEN1KMT2AALDH1A1 | |
| SCHEMBL17912757 | 0.66 | RORC (0.65) | RORCPPARGDOT1LCYP2C9 | |
| SCHEMBL4321632 | 0.65 | CNR1 (0.59) | RORCPPARGMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550771-B2 | Keto-imidazopyridine derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550771-B2 | Keto-imidazopyridine derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550771-B2 | Keto-imidazopyridine derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160272631-A1 | KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272631-A1 | KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272631-A1 | KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015036411-A1 | KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272631-A1 | KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | RORC 1/4885PPARG 132/4885DOT1L 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.